<DOC>
	<DOC>NCT00629551</DOC>
	<brief_summary>The main purpose of this study is to evaluate the efficacy of saredutant 100mg or 30mg once daily in combination with paroxetine 20mg once daily compared to saredutant placebo in combination with paroxetine 20mg once daily in patients with major depressive disorder. The study also includes a double-placebo group (saredutant placebo in combination with paroxetine placebo).</brief_summary>
	<brief_title>An Eight-week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<criteria>Outpatients with recurrent Major Depressive Disorder Symptoms of current depressive episode for less than 30 days or more than 2 years Mild depression, as measured by standard clinical research scales Significant suicide risk Lack of sexual activity (including masturbation) Other psychiatric conditions that would obscure the results of the study History of failure to respond to antidepressant treatment Pregnancy or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Depression</keyword>
	<keyword>Major Depressive Episode</keyword>
	<keyword>Antidepressant</keyword>
</DOC>